Explain this page
Arphra AIPlain-English read on Merck & Co., Inc.’s valuationTransactions
14
0 buys · 14 sells
Bought
$0
Open market
Sold
$30.84M
Open market
Net flow
−$30.84M
Buys − sells
Transactions
| Insider | Role | Action | Shares | Price | Value | Trade date | Filing |
|---|---|---|---|---|---|---|---|
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | 10,000 | $121.46 | $1.21M | Feb 12, 2026 | Feb 12, 2026 |
| Li Dean Y | officer: Executive VP & President, MRL | Sell | 10,235 | $117.52 | $1.2M | Feb 10, 2026 | Feb 10, 2026 |
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | 10,000 | $118.41 | $1.18M | Feb 09, 2026 | Feb 09, 2026 |
| Zachary Jennifer | officer: EVP, General Counsel | Sell | 38,835 | $119.15 | $4.63M | Feb 09, 2026 | Feb 09, 2026 |
| Williams David Michael | officer: EVP,Chief Info&Digital Officer | Sell | 5,000 | $121.91 | $609.53K | Feb 06, 2026 | Feb 06, 2026 |
| Oosthuizen Johannes Jacobus | officer: President, U.S. Market | Sell | 15,000 | $121.87 | $1.83M | Feb 06, 2026 | Feb 06, 2026 |
| DeLuca Richard R. | officer: EVP&Pres, Merck Animal Heallth | Sell | 37,685 | $120.92 | $4.56M | Feb 06, 2026 | Feb 06, 2026 |
| Guindo Chirfi | officer: Chief Marketing Officer | Sell | 20,000 | $121.88 | $2.44M | Feb 05, 2026 | Feb 06, 2026 |
| Smart Dalton E. III | officer: SVP Fin. - Global Controller | Sell | 4,000 | $119.68 | $478.7K | Feb 04, 2026 | Feb 06, 2026 |
| Davis Robert M | director, officer: Chairman, CEO & President | Sell | 32,462 | $118.35 | $3.84M | Feb 04, 2026 | Feb 06, 2026 |
| Li Dean Y | officer: Executive VP & President, MRL | Sell | 15,087 | $118.77 | $1.79M | Feb 04, 2026 | Feb 06, 2026 |
| Litchfield Caroline | officer: EVP & CFO | Sell | 41,997 | $119.61 | $5.02M | Feb 04, 2026 | Feb 06, 2026 |
| Smart Dalton E. III | officer: SVP Fin. - Global Controller | Sell | 2,400 | $119.68 | $287.22K | Feb 04, 2026 | Feb 06, 2026 |
| Davis Robert M | director, officer: Chairman, CEO & President | Sell | 14,972 | $117.38 | $1.76M | Feb 04, 2026 | Feb 06, 2026 |
By insider
- Davis Robert M−$5.6Mdirector, officer: Chairman, CEO & President0B · 2S
- Litchfield Caroline−$5.02Mofficer: EVP & CFO0B · 1S
- Guindo Chirfi−$4.84Mofficer: Chief Marketing Officer0B · 3S
- Zachary Jennifer−$4.63Mofficer: EVP, General Counsel0B · 1S
- DeLuca Richard R.−$4.56Mofficer: EVP&Pres, Merck Animal Heallth0B · 1S
- Li Dean Y−$2.99Mofficer: Executive VP & President, MRL0B · 2S
- Oosthuizen Johannes Jacobus−$1.83Mofficer: President, U.S. Market0B · 1S
- Smart Dalton E. III−$765.92Kofficer: SVP Fin. - Global Controller0B · 2S
- Williams David Michael−$609.53Kofficer: EVP,Chief Info&Digital Officer0B · 1S
Beneficial ownership filings
Schedule 13D / 13G — investors holding more than 5% of MRK-US.
DB · acquisition_ownership6
| Filed | Reporting person | Form | Type | Aggregate owned | % Class | Sole voting | Shared voting | Citizenship | |
|---|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Merck Global Health Innovation Fund, LLC | — | OO | — | +11.40% | 0 | 4.6M | New Jersey | SEC → |
| Jan 23, 2024 | Merck Sharp & Dohme LLC | — | OO | — | +11.40% | 0 | 4.6M | New Jersey | SEC → |
| Jan 23, 2024 | Merck & Co., Inc. | — | HC, CO | — | +11.40% | 0 | 4.6M | New Jersey | SEC → |
| Feb 02, 2022 | Merck Sharp & Dohme Corp. | — | CO | — | +6.60% | 0 | 12.15M | New Jersey | SEC → |
| Feb 02, 2022 | Merck & Co., Inc. | — | HC, CO | — | +6.60% | 0 | 12.15M | New Jersey | SEC → |
| Feb 01, 2022 | (1) BlackRock, Inc. | — | HC | — | +7.80% | 171.96M | 0 | Delaware | SEC → |
Top 10 holders · 8 quarters
13F position evolutionNo 13F history in
institutional_holders for MRK-US.